Jiang Su Yida Chemical (300721.SZ) plans to raise no more than 636 million yuan through a private placement of shares.
Yida Chemical (300721.SZ) has released its 2026 private placement plan for issuing shares to specific targets. The total amount of funds raised through this private placement will not exceed 636 million yuan (inclusive of this amount). After deducting issuance expenses, the raised funds will be used for the following projects: an annual production of 200,000 tons of propylene oxide (ethylene) oxide derivatives project, and the technical renovation project for purification, blending, and filling of 25,000 tons per year (PM, PMA, Thinner liquid) at Zhuhai Yida Chemical Co., Ltd.
Jiang Su Yida Chemical (300721.SZ) has released its 2026 plan for issuing shares to specific targets. The total amount of funds raised through this issuance to specific targets shall not exceed 636 million yuan (inclusive of this amount). After deducting issuance expenses, the raised funds will be used for the following projects: an annual production project of 200,000 tons of propylene oxide (ethylene oxide) derivatives, and the technical renovation project of Zhuhai Yida Chemical Co., Ltd. for the purification, blending, and filling of 25,000 tons per year (PM, PMA, Thinner liquid).
Related Articles
Zhangzhou Pientzehuang Pharmaceutical (600436.SH) Chairman Lin Zhihui leaves office due to work adjustment.
Zelgen Biopharmaceutical (688266.SH): New Drug Application for Gecacitinib Hydrochloride Tablets for the Treatment of Active Ankylosing Spondylitis Accepted
Services and wealth management businesses become key "engine"! Citigroup (C.US) Q3 net profit surges 40% year-over-year, EPS beats expectations.
Zhangzhou Pientzehuang Pharmaceutical (600436.SH) Chairman Lin Zhihui leaves office due to work adjustment.
Zelgen Biopharmaceutical (688266.SH): New Drug Application for Gecacitinib Hydrochloride Tablets for the Treatment of Active Ankylosing Spondylitis Accepted
Services and wealth management businesses become key "engine"! Citigroup (C.US) Q3 net profit surges 40% year-over-year, EPS beats expectations.
